Related scientific articles (all)

Personalised cancer management: closer, but not here yet.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial.

Authors : Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 903-9

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors : Pinto AC, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Asthma control measurement using five different questionnaires: A prospective study.

Authors : Vermeulen F, de Meulder I, Paesmans M, Muylle I, Bruyneel M, Ninane V
Year : 2013
Journal : Respir Med
Volume : 107(9)
Pages : 1314-21

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Authors : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pages : 3219-28

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Authors : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 682-90

Distinct tumor protein p53 mutants in breast cancer subgroups.

Authors : Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H
Year : 2013
Journal : Int. J. Cancer
Volume : 132(5)
Pages : 1227-31

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Authors : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Year : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Authors : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1980-5

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Year : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Stem cell transplantation can provide durable disease control in Blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Authors : Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
Year : 2013
Journal : Blood
Volume : 121(3)
Pages : 440-446

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Authors : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5

Liquid-Based Cytology of the Breast: Pitfalls Unrecognized before Specific Liquid-Based Cytology Training - Proposal for a Modification of the Diagnostic Criteria.

Authors : Feoli F, Ameye L, Van Eeckhout P, Paesmans M, Marra V, Arisio R
Year : 2013
Journal : Acta Cytol.
Volume : 57(4)
Pages : 369-76

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Authors : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pages : 654-63

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Authors : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 606-15

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Authors : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Year : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Authors : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Year : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73

Thoracic oncology: annual review.

Authors : Sculier JP, Berghmans T, Meert AP
Year : 2013
Journal : Rev Med Brux
Volume : 34(2)
Pages : 100-11

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Year : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8